Literature Review: Drug and Alcohol-Induced Hypoglycaemia
Open accessAbstract
Objective: Narrative literature review of medication and alcohol related hypoglycaemia.Background: Drugs and alcohol are the commonest causes of hypoglycaemia and account for a significant number of emergency department attendances and hospital admissions.Methods: Hypoglycaemia risk with various drug classes and alcohol is discussed along with underlying mechanisms, characteristics and caveats around the diagnosis and management.Conclusions: Hypoglycaemia is most common with insulin treatment in type 1 diabetes but insulin in type 2 diabetes, sulphonylureas, other anti-hyperglycaemic medications and medications from other classes like beta-blockers, angiotensin converting enzyme inhibitors, fibrates, psychotropic medications, anti-malarial drugs, antibiotics, anti-arrhythmic drugs, non-steroidal anti-inflammatory agents, and a few other classes of medications may also increase hypoglycaemia risk. The risk, depending on the drug class, may be as monotherapy or when used in combination with anti-hyperglycaemic medications and may either be in the therapeutic doses or only in overdose. Alcohol has profound effects on glucose metabolism. However, the incidence of alcohol-induced hypoglycaemia in healthy individuals with good glycogen reserve is low. Glycogenolysis plays an initial role in the defence against alcohol-induced hypoglycaemia and gluconeogenesis takes over later on to prevent profound hypoglycaemia. There are inconstancies in the literature about the role of counter-regulatory hormones in alcohol-induced hypoglycaemia.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ethanol metabolism increases NADH, which inhibits two primary steps in gluconeogenesis: conversion of lactate into pyruvate and oxaloacetate into malate.
“Ethanol is metabolized by alcohol dehydrogenase, which reduces NAD+ to NADH in the oxidative process. The increased NADH level inhibits two primary steps in gluconeogenesis: the conversion of lactate into pyruvate and oxaloacetate into malate [18].”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [18]
The Alcohol metabolism passage (indexed under References; page not provided) says alcohol dehydrogenase reduces NAD to NADH. The gluconeogenesis passage says increased NADH inhibits lactate-to-pyruvate conversion, but identifies the other affected step as malate-to-oxaloacetate conversion—the reverse of the direction claimed. (LLM, conf=0.91)
Experimental — accuracy not yet measuredIn the setting of poor nutritional status or impaired hepatic function, glycogen stores are likely already depleted, leading to increased risk for hypoglycemia.
“However, in the setting of poor nutritional status or impaired hepatic function, glycogen stores are likely already depleted, leading to an increased risk for hypoglycemia.”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [18]
In “Role of hepatic auto-regulation” (page unavailable), the review says poor nutrition and impaired liver function increase the risk of alcohol-induced hypoglycaemia. It also says hypoglycaemia can occur after glycogen stores are used up, but does not say those stores are likely already depleted in either condition. The claimed explanation is therefore not fully supported. (LLM, conf=0.85)
Experimental — accuracy not yet measuredIn a healthy individual without risk factors, alcohol usually does not cause hypoglycemia because it also stimulates hepatic glycogenolysis.
“In a healthy individual without risk factors, this usually does not cause issues, as alcohol also stimulates hepatic glycogenolysis [18].”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [18]
In patients with diabetes, alcohol ingestion is associated with a reduction in growth hormone levels, which may attenuate counterregulatory responses to hypoglycemia.
“In addition, in patients with diabetes, studies have found that alcohol ingestion is associated with a reduction in growth hormone levels, which may attenuate counterregulatory responses to hypoglycemia [18].”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [18]
Sulfonylureas and meglitinides bind to different domains on sulfonylurea receptors expressed on pancreatic β-cells, promoting closure of KATP channels and subsequent insulin release.
“These two classes bind to different domains on sulfonylurea receptors expressed on pancreatic β -cells, promoting closure of KATP channels and subsequent insulin release [18].”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893 · see citing works
RIZZA, R. A., MANDARINO, L. J., & GERICH, J. E. (1982) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-54-1-131 · Cited by 696 · cited 1× · see citing works
“Whereas cortisol reduces insulin sensitivity in hepatic as well as extrahepatic tissues to create a state of insulin resistance (159).”
BackgroundVaccaro, O., Masulli, M., Nicolucci, A., Bonora, E., Del Prato, S., Maggioni, A. P., Rivellese, A. A., Squatrito, S., Giorda, C. B., Sesti, G., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30317-0 · Cited by 292 · see citing works
Neuroendocrine responses to hypoglycemia
Tesfaye, N., & Seaquist, E. R. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05820.x · Cited by 164 · see citing works
Acarbose in the treatment of elderly patients with type 2 diabetes
Josse, R. G., Chiasson, J.-L., Ryan, E. A., Lau, D. C. W., Ross, S. A., Yale, J.-F., Leiter, L. A., Maheux, P., Tessier, D., Wolever, T. M. S., et al. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00176-6 · Cited by 110 · see citing works
Bolli, G. B., Tsalikian, E., Haymond, M. W., Cryer, P. E., & Gerich, J. E. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111359 · Cited by 108 · see citing works
Flagged first, then by citations
Research works printed but not linked: 164
- Guettier JM, Gorden P. Hypoglycemia. Endocrinol Metab Clin North Am 2006;35:753-66. viii-ix. [Crossref] [PubMed]
- Marks V, Teale JD. Drug-induced hypoglycemia. Endocrinol Metab Clin North Am 1999;28:555-77. [Crossref] [PubMed]
- Kilbridge PM, Campbell UC, Cozart HB, et al. Automated surveillance for adverse drug events at a community hospital and an academic medical center. J Am Med Inform Assoc 2006;13:372-7. [Crossref] [PubMed]
- Chan TY, Lee KK, Chan AW, et al. Utilization of antidiabetic drugs in Hong Kong: relation to the common occurrence of antidiabetic drug-induced hypoglycemia amongst acute medical admissions and the relative prevalence of NIDDM. Int J Clin Pharmacol Ther 1996;34:43-6. [PubMed]
- Ben Salem C, Fathallah N, Hmouda H, et al. Drug-induced hypoglycaemia: an update. Drug Saf 2011;34:21-45. [Crossref] [PubMed]
- Brown TM, Harvey AM. Spontaneous hypoglycemia in “smoke” drinkers. JAMA 1941;117:12-5. [Crossref]
- Furman BL. Antidiabetic Agents. In: Enna SJ, Bylund DB. editors. xPharm: The Comprehensive Pharmacology Reference. New York: Elsevier, 2007:1.
- Maloney A, Rosenstock J, Fonseca V. A Model-Based Meta-Analysis of 24 Antihyperglycemic Drugs for Type 2 Diabetes: Comparison of Treatment Effects at Therapeutic Doses. Clin Pharmacol Ther 2019;105:1213-23. [Crossref] [PubMed]
- Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 2004;64:1339-58. [Crossref] [PubMed]
- Holstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 2005;60:103-6. [Crossref] [PubMed]
- Schopman JE, Simon AC, Hoefnagel SJ, et al. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev 2014;30:11-22. [Crossref] [PubMed]
- Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42. [Crossref] [PubMed]
- Leiter LA, Shestakova MV, Trubitsyna NP, et al. Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation. Diabetes Res Clin Pract 2016;112:50-6. [Crossref] [PubMed]
- Klein-Schwartz W, Stassinos GL, Isbister GK. Treatment of sulfonylurea and insulin overdose. Br J Clin Pharmacol 2016;81:496-504. [Crossref] [PubMed]
- DeWitt CR, Heard K, Waksman JC. Insulin & C-peptide levels in sulfonylurea-induced hypoglycemia: a systematic review. J Med Toxicol 2007;3:107-18. [Crossref] [PubMed]
- Lheureux PE, Zahir S, Penaloza A, et al. Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide. Crit Care 2005;9:543-9. [Crossref] [PubMed]
- Melo KFS, Bahia LR, Pasinato B, et al. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 2019;11:2. [Crossref] [PubMed]
- Fullerton B, Siebenhofer A, Jeitler K, et al. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev 2018;12:CD013228 [Crossref] [PubMed]
- Cheng AYY, Patel DK, Reid TS, et al. Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. Adv Ther 2019;36:1018-30. [Crossref] [PubMed]
- Lipska KJ, Parker MM, Moffet HH, et al. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin with Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. JAMA 2018;320:53-62. [Crossref] [PubMed]
- Semlitsch T, Engler J, Siebenhofer A, et al. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2020;11:CD005613 [PubMed]
- Laranjeira FO, de Andrade KRC, Figueiredo ACMG, et al. Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials. PLoS One 2018;13:e0194801 [Crossref] [PubMed]
- Janež A, Guja C, Mitrakou A, et al. Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review. Diabetes Ther 2020;11:387-409. [Crossref] [PubMed]
- Pang T, Bain SC, Black RNA, et al. A multicentre, UK, retrospective, observational study to assess the effectiveness of insulin glargine 300 units/ml in treating people with Type 1 diabetes mellitus in routine clinical practice (SPARTA). Diabet Med 2019;36:110-9. [Crossref] [PubMed]
- Sleeman A, Odom J, Schellinger M. Comparison of Hypoglycemia and Safety Outcomes With Long-Acting Insulins Versus Insulin NPH in Pregestational and Gestational Diabetes. Ann Pharmacother 2020;54:669-75. [Crossref] [PubMed]
- Rickels MR, Peleckis AJ, Dalton-Bakes C, et al. Continuous Glucose Monitoring for Hypoglycemia Avoidance and Glucose Counterregulation in Long-Standing Type 1 Diabetes. J Clin Endocrinol Metab 2018;103:105-14. [Crossref] [PubMed]
- Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet 2018;391:1367-77. [Crossref] [PubMed]
- Haak T, Hanaire H, Ajjan R, et al. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. Diabetes Ther 2017;8:55-73. [Crossref] [PubMed]
- Choudhary P, Ramasamy S, Green L, et al. Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes. Diabetes Care 2013;36:4160-2. [Crossref] [PubMed]
- Marks V. Insulin and the law. Ann Clin Biochem 2015;52:696-8. [Crossref] [PubMed]
- Uchida J, Oikawa Y, Katsuki T, et al. Insulin degludec overdose may lead to long-lasting hypoglycaemia through its markedly prolonged half-life. Diabet Med 2018;35:277-80. [Crossref] [PubMed]
- Lu M, Inboriboon PC. Lantus insulin overdose: a case report. J Emerg Med 2011;41:374-7. [Crossref] [PubMed]
- Oduru M, Ahmad M. Massive levemir (long-acting) insulin overdose: case report. Case Rep Med 2012;2012:904841 [Crossref] [PubMed]
- Thapa S, Fahim G, Ganne S. Inadvertent iatrogenic insulin detemir 1000 units overdose in a hospitalised patient. BMJ Case Rep 2019;12:224999 [Crossref] [PubMed]
- Thewjitcharoen Y, Lekpittaya N, Himathongkam T. Attempted suicide by massive insulin injection: a case report and review of the literature. J Med Assoc Thai 2008;91:1920-4. [PubMed]
- Parfitt C, Church D, Armston A, et al. Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues. Clin Biochem 2015;48:1354-7. [Crossref] [PubMed]
- Wróbel MP, Marek B, Kajdaniuk D, et al. Metformin - a new old drug. Endokrynol Pol 2017;68:482-96. [Crossref] [PubMed]
- Roumie CL, Min JY, Greevy RA, et al. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea. CMAJ 2016;188:E104-12. [Crossref] [PubMed]
- Sugihara H, Nagao M, Harada T, et al. Comparison of three α-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes. J Diabetes Investig 2014;5:206-12. [Crossref] [PubMed]
- Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999;22:960-4. [Crossref] [PubMed]
- Hedrington MS, Davis SN. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes. Expert Opin Pharmacother 2019;20:2229-35. [Crossref] [PubMed]
- Arnold SV, Inzucchi SE, Echouffo-Tcheugui JB, et al. Understanding Contemporary Use of Thiazolidinediones. Circ Heart Fail 2019;12:e005855 [Crossref] [PubMed]
- Leonard CE, Han X, Brensinger CM, et al. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study. Pharmacoepidemiol Drug Saf 2018;27:9-18. [Crossref] [PubMed]
- Grant JS, Graven LJ. Progressing From Metformin to Sulfonylureas or Meglitinides. Workplace Health Saf 2016;64:433-9. [Crossref] [PubMed]
- Bailey T. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med 2013;126:S10-20. [Crossref] [PubMed]
- Moses R. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert Opin Pharmacother 2000;1:1455-67. [Crossref] [PubMed]
- Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27:1265-70. [Crossref] [PubMed]
- Scheen AJ. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007;46:93-108. [Crossref] [PubMed]
- Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One 2015;10:e0125879 [Crossref] [PubMed]
- Sesti G, Avogaro A, Belcastro S, et al. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol 2019;56:605-17. [Crossref] [PubMed]
- Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf 2018;17:387-405. [Crossref] [PubMed]
- Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2015;6:19-28. [Crossref] [PubMed]
- Aroda VR. A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab 2018;20:22-33. [Crossref] [PubMed]
- Bucheit JD, Pamulapati LG, Carter N, et al. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. Diabetes Technol Ther 2020;22:10-8. [Crossref] [PubMed]
- Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2017;24:73-9. [PubMed]
- Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf 2019;18:295-311. [Crossref] [PubMed]
- Zaccardi F, Webb DR, Htike ZZ, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab 2016;18:783-94. [Crossref] [PubMed]
- Frandsen CS, Dejgaard TF, Madsbad S, et al. Non-insulin pharmacological therapies for treating type 1 diabetes. Expert Opin Pharmacother 2018;19:947-60. [Crossref] [PubMed]
- Mills GA, Horn JR. Beta-blockers and glucose control. Drug Intell Clin Pharm 1985;19:246-51. [Crossref] [PubMed]
- Casiglia E, Tikhonoff V. Long-Standing Problem of β-Blocker-Elicited Hypoglycemia in Diabetes Mellitus. Hypertension 2017;70:42-3. [Crossref] [PubMed]
- Grajower MM, Walter L, Albin J. Hypoglycemia in chronic hemodialysis patients: association with propranolol use. Nephron 1980;26:126-9. [Crossref] [PubMed]
- Holm G, Herlitz J, Smith U. Severe hypoglycaemia during physical exercise and treatment with beta-blockers. Br Med J (Clin Res Ed) 1981;282:1360. [Crossref] [PubMed]
- Zaccardi F, Nystrup Husemoen LL, Thorsted BL, et al. Selectivity of beta-blockers, cardiovascular and all-cause mortality in people with hypoglycaemia: An observational study. Nutr Metab Cardiovasc Dis 2019;29:481-8. [Crossref] [PubMed]
- Chen M, Robertson RP. Restoration of the acute insulin response by sodium salicylate. A glucose dose-related phenomenon. Diabetes 1978;27:750-6. [Crossref] [PubMed]
- Bratusch-Marrain PR, Vierhapper H, Komjati M, et al. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man. Diabetologia 1985;28:671-6. [Crossref] [PubMed]
- Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-6. [Crossref] [PubMed]
- Reid J, Lightbody TD. The insulin equivalence of salicylate. Br Med J 1959;1:897-900. [Crossref] [PubMed]
- Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996;15:135-57. [Crossref] [PubMed]
- Maurer TA, Winter ME, Koo J, et al. Refractory hypoglycemia: a complication of topical salicylate therapy. Arch Dermatol 1994;130:1455-7. [Crossref] [PubMed]
- Ruvalcaba RH, Limbeck GA, Kelley VC. Acetaminophen and hypoglycemia. Am J Dis Child 1966;112:558-60. [PubMed]
- Thomson JS, Prescott LF. Liver damage and impaired glucose tolerance after paracetamol overdosage. Br Med J 1966;2:506-7. [Crossref] [PubMed]
- Lee HT, Tseng WC, Tarng DC. Recurrent hypoglycemia in a hemodialysis patient related to propoxyphene treatment. J Chin Med Assoc 2007;70:286-8. [Crossref] [PubMed]
- Grandvuillemin A, Jolimoy G, Authier F, et al. Tramadol-induced hypoglycemia. 2 cases. Presse Med 2006;35:1842-4. [Crossref] [PubMed]
- Choi SB, Jang JS, Park S. Tramadol enhances hepatic insulin sensitivity via enhancing insulin signaling cascade in the cerebral cortex and hypothalamus of 90% pancreatectomized rats. Brain Res Bull 2005;67:77-86. [Crossref] [PubMed]
- Mohr JF, McKinnon PS, Peymann PJ, et al. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 2005;25:1303-9. [Crossref] [PubMed]
- El Ghandour S, Azar ST. Dysglycemia associated with quinolones. Prim Care Diabetes 2015;9:168-71. [Crossref] [PubMed]
- Granados J, Ceballos M, Amariles P. Hypo or hyperglycemia associated with fluoroquinolone use. Rev Med Chil 2018;146:618-26. [Crossref] [PubMed]
- Kennedy KE, Teng C, Patek TM, et al. Hypoglycemia Associated with Antibiotics Alone and in Combination with Sulfonylureas and Meglitinides: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS). Drug Saf 2020;43:363-9. [Crossref] [PubMed]
- Saraya A, Yokokura M, Gonoi T, et al. Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004;497:111-7. [Crossref] [PubMed]
- Ito M, Fukuda M, Suzuki Y, et al. Carnitine-related hypoglycemia caused by 3 days of pivalate antibiotic therapy in a patient with severe muscular dystrophy: a case report. BMC Pediatr 2017;17:73. [Crossref] [PubMed]
- Khamaisi M, Leitersdorf E. Severe hypoglycemia from clarithromycin-repaglinide drug interaction. Pharmacotherapy 2008;28:682-4. [Crossref] [PubMed]
- Niemi M, Neuvonen PJ, Kivistö KT. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther 2001;70:58-65. [Crossref] [PubMed]
- Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 2007;46:1039-49. [Crossref] [PubMed]
- Ruan XC, Tan PY, Tan Y. Clarithromycin and Glipizide Drug-drug Interaction Leading to Refractory Hypoglycemia. Cureus 2019;11:e4800 [Crossref] [PubMed]
- Basaria S, Braga M, Moore WT. Doxycycline-induced hypoglycemia in a nondiabetic young man. South Med J 2002;95:1353-4. [Crossref] [PubMed]
- Tan CH, Shelley C, Harman KE. Doxycycline-induced hypoglycaemia. Clin Exp Dermatol 2016;41:43-4. [Crossref] [PubMed]
- Miller JB. Hypoghycaemic effect of oxytetracycline. Br Med J 1966;2:1007. [Crossref] [PubMed]
- Forde DG, Aberdein J, Tunbridge A, et al. Hypoglycaemia associated with co-trimoxazole use in a 56-year-old Caucasian woman with renal impairment. BMJ Case Rep 2012;2012:bcr2012007215 [Crossref] [PubMed]
- Gonc EN, Turul T, Yordam N, et al. Trimethoprim-sulfamethoxazole induced prolonged hypoglycemia in an infant with MHC class II deficiency: diazoxide as a treatment option. J Pediatr Endocrinol Metab 2003;16:1307-9. [PubMed]
- Ray A, Sharma S, Atal S, et al. Tigecycline-Induced Severe Hypoglycemia in a Non-Diabetic Individual: A Case Report and Brief Review of Tigecycline-Induced Severe Hypoglycemia. Am J Case Rep 2020;21:e924556 [Crossref] [PubMed]
- Ogetii GN, Akech S, Jemutai J, et al. Hypoglycaemia in severe malaria, clinical associations and relationship to quinine dosage. BMC Infect Dis 2010;10:334. [Crossref] [PubMed]
- Lalloo DG, Shingadia D, Bell DJ, et al. UK malaria treatment guidelines 2016. J Infect 2016;72:635-49. [Crossref] [PubMed]
- Phillips RE, Looareesuwan S, White NJ, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed) 1986;292:1319-21. [Crossref] [PubMed]
- Phillips RE, Warrell DA, Looareesuwan S, et al. Effectiveness of SMS 201-995, a synthetic, long-acting somatostatin analogue, in treatment of quinine-induced hyperinsulinaemia. Lancet 1986;1:713-6. [Crossref] [PubMed]
- Assan R, Perronne C, Chotard L, et al. Mefloquine-associated hypoglycaemia in a cachectic AIDS patient. Diabete Metab 1995;21:54-8. [PubMed]
- Baretić M. Case report of chloroquine therapy and hypoglycaemia in type 1 diabetes: What should we have in mind during the COVID-19 pandemic? Diabetes Metab Syndr 2020;14:355-6. [Crossref] [PubMed]
- El-Solia A, Al-Otaibi K, Ai-Hwiesh AK. Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis. BMJ Case Rep 2018;2018:bcr-2017-223639 [Crossref] [PubMed]
- Fairhurst RM, Sadou B, Guindo A, et al. Case report: life-threatening hypoglycaemia associated with sulfadoxine-pyrimethamine, a commonly used antimalarial drug. Trans R Soc Trop Med Hyg 2003;97:595-6. [Crossref] [PubMed]
- Croxson MS, Shaw DW, Henley PG, et al. Disopyramide-induced hypoglycaemia and increased serum insulin. N Z Med J 1987;100:407-8. [PubMed]
- Cacoub P, Deray G, Baumelou A, et al. Disopyramide-induced hypoglycemia: case report and review of the literature. Fundam Clin Pharmacol 1989;3:527-35. [Crossref] [PubMed]
- Abe M, Maruyama T, Fujii Y, et al. Disopyramide-induced hypoglycemia in a non-diabetic hemodialysis patient: a case report and review of the literature. Clin Nephrol 2011;76:401-6. [Crossref] [PubMed]
- Negishi M, Shimomura K, Proks P, et al. Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med 2009;26:76-8. [Crossref] [PubMed]
- Biagetti B, Corcoy R. Hypoglycemia associated with fluoxetine treatment in a patient with type 1 diabetes. World J Clin Cases 2013;1:169-71. [Crossref] [PubMed]
- Santra Dhali R, Banerjee P, Munshi S, et al. Hypoglycemic episodes in a case of Prementrual Dysphoric Disorder on sertraline. Indian J Pharmacol 2015;47:567-8. [Crossref] [PubMed]
- Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm 2011;33:484-92. [Crossref] [PubMed]
- Duncan RA, Armstrong PA, Paterson B. Severe hypoglycaemia in citalopram overdose. Eur J Emerg Med 2008;15:234-5. [Crossref] [PubMed]
- Francino MC, Bretaudeau Deguigne M, Badin J, et al. Hypoglycaemia: a little known effect of Venlafaxine overdose. Clin Toxicol (Phila) 2012;50:215-7. [Crossref] [PubMed]
- Ibrahim FA, Rashid F, Hussain AA, et al. Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case report. J Med Case Rep 2017;11:29. [Crossref] [PubMed]
- Rowland MJ, Bransome ED Jr, Hendry LB. Hypoglycemia caused by selegiline, an antiparkinsonian drug: can such side effects be predicted? J Clin Pharmacol 1994;34:80-5. [Crossref] [PubMed]
- Couto J, Dos Santos LP, Mendes T, et al. Life-threatening hypoglycemia attributable to haloperidol in a patient with schizophrenia. Braz J Psychiatry 2019;41:190-1. [Crossref] [PubMed]
- Nagamine T. Severe hypoglycemia associated with risperidone. Psychiatry Clin Neurosci 2016;70:421. [Crossref] [PubMed]
- Cho SJ, Lee SA. Quetiapine-Induced Severe Hypoglycemia in Patient Without Diabetes Mellitus: A Case Report. Ann Geriatr Med Res 2019;23:35-7. [Crossref] [PubMed]
- Fujita T, Mizoguchi Y, Kunitake Y, et al. Second-Generation Antipsychotic-Induced Hypoglycemia. Prim Care Companion CNS Disord 2018;20:17br02186.
- Herings RM, de Boer A, Stricker BH, et al. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995;345:1195-8. [Crossref] [PubMed]
- Jarred G, Kennedy RL. Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patient. Ther Adv Endocrinol Metab 2010;1:23-8. [Crossref] [PubMed]
- Grégoire F, Pariente A, Fourrier-Reglat A, et al. A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding. Br J Clin Pharmacol 2008;66:142-5. [Crossref] [PubMed]
- Leonard CE, Bilker WB, Brensinger CM, et al. Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics. Clin Pharmacol Ther 2016;99:538-47. [Crossref] [PubMed]
- Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes. Expert Opin Drug Saf 2012;11:597-614. [Crossref] [PubMed]
- Leonard CE, Han X, Bilker WB, et al. Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics. Diabetes Res Clin Pract 2016;115:60-7. [Crossref] [PubMed]
- Boden G. Interaction between free fatty acids and glucose metabolism. Curr Opin Clin Nutr Metab Care 2002;5:545-9. [Crossref] [PubMed]
- Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care 1995;18:47-55. [Crossref] [PubMed]
- Okazaki M, Okazaki M, Nakamura M, et al. Consecutive hypoglycemia attacks induced by co-trimoxazole followed by pentamidine in a patient with acquired immunodeficiency syndrome. Int J STD AIDS 2019;30:86-9. [Crossref] [PubMed]
- Ariyasu H, Inaba H, Ota T, et al. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma. In Vivo 2018;32:345-51. [PubMed]
- Bonilla E, Lee YY, Phillips PE, et al. Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus. Ann Rheum Dis 2007;66:1688. [Crossref] [PubMed]
- Fallahi P, Ferrari SM, Elia G, et al. THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors. Eur J Endocrinol 2021;184:R29-40. [Crossref] [PubMed]
- Brooks MB. Erlotinib appears to produce prolonged remission of insulin-requiring type 2 diabetes associated with metabolic syndrome and chronic kidney disease. The British Journal of Diabetes & Vascular Disease 2012;12:87-90. [Crossref]
- Kristensen PL, Pedersen-Bjergaard U, Thorsteinsson B. Varenicline may trigger severe hypoglycaemia in Type 1 diabetes. Diabet Med 2008;25:625-6. [Crossref] [PubMed]
- Ernst AA, Jones K, Nick TG, et al. Ethanol ingestion and related hypoglycemia in a pediatric and adolescent emergency department population. Acad Emerg Med 1996;3:46-9. [Crossref] [PubMed]
- Sporer KA, Ernst AA, Conte R, et al. The incidence of ethanol-induced hypoglycemia. Am J Emerg Med 1992;10:403-5. [Crossref] [PubMed]
- Sucov A, Woolard RH. Ethanol-associated hypoglycemia is uncommon. Acad Emerg Med 1995;2:185-9. [Crossref] [PubMed]
- Hammerstedt H, Chamberlain SL, Nelson SW, et al. Alcohol-related hypoglycemia in rural Uganda: socioeconomic and physiologic contrasts. Int J Emerg Med 2011;4:5. [Crossref] [PubMed]
- Cederbaum AI. Alcohol metabolism. Clin Liver Dis 2012;16:667-85. [Crossref] [PubMed]
- Vonghia L, Leggio L, Ferrulli A, et al. Acute alcohol intoxication. Eur J Intern Med 2008;19:561-7. [Crossref] [PubMed]
- Bolli G, De Feo P, Perriello G, et al. Role of hepatic autoregulation in defense against hypoglycemia in humans. J Clin Invest 1985;75:1623-31. [Crossref] [PubMed]
- Yki-Järvinen H, Koivisto VA, Ylikahri R, et al. Acute effects of ethanol and acetate on glucose kinetics in normal subjects. Am J Physiol 1988;254:E175-80. [PubMed]
- Field JB, Williams HE, Mortimore GE. Studies on the mechanism of ethanol-induced hypoglycemia. J Clin Invest 1963;42:497-506. [Crossref] [PubMed]
- Searle GL, Shames D, Cavalieri RR, et al. Evaluation of ethanol hypoglycemia in man: turnover studies with C-6 14C glucose. Metabolism 1974;23:1023-35. [Crossref] [PubMed]
- Williams HE. Alcoholic hypoglycemia and ketoacidosis. Med Clin North Am 1984;68:33-8. [Crossref] [PubMed]
- Mokuda O, Tanaka H, Hayashi T, et al. Ethanol stimulates glycogenolysis and inhibits both glycogenesis via gluconeogenesis and from exogenous glucose in perfused rat liver. Ann Nutr Metab 2004;48:276-80. [Crossref] [PubMed]
- Siler SQ, Neese RA, Christiansen MP, et al. The inhibition of gluconeogenesis following alcohol in humans. Am J Physiol 1998;275:E897-907. [PubMed]
- Lecavalier L, Bolli G, Cryer P, et al. Contributions of gluconeogenesis and glycogenolysis during glucose counterregulation in normal humans. Am J Physiol 1989;256:E844-51. [PubMed]
- Wright J, Marks V. Alcohol-induced hypoglycaemia. Adv Exp Med Biol 1980;126:479-83. [Crossref] [PubMed]
- Baker SG, Joffe BI, Shires R, et al. Alcohol-potentiated reactive hypoglycaemia depends on the nature of the carbohydrate ingested at the same time. Alcohol Alcohol 1984;19:45-9. [PubMed]
- Joffe BI, Seftel HC, Van As M. Hormonal responses in ethanol-induced hypoglycemia. J Stud Alcohol 1975;36:550-4. [Crossref] [PubMed]
- Dillon ES, Dyer WW, Smelo LS. Ketone Acidosis in Nondiabetic Adults. Med Clin North Am 1940;24:1813-22. [Crossref]
- McGuire LC, Cruickshank AM, Munro PT. Alcoholic ketoacidosis. Emerg Med J 2006;23:417-20. [Crossref] [PubMed]
- Jain H, Beriwal S, Singh S. Alcohol induced ketoacidosis, severe hypoglycemia and irreversible encephalopathy. Med Sci Monit 2002;8:CS77-9. [PubMed]
- Wrenn KD, Slovis CM, Minion GE, et al. The syndrome of alcoholic ketoacidosis. Am J Med 1991;91:119-28. [Crossref] [PubMed]
- Noor NM, Basavaraju K, Sharpstone D. Alcoholic ketoacidosis: a case report and review of the literature. Oxf Med Case Reports 2016;2016:31-3. [Crossref] [PubMed]
- Gerrity RS, Pizon AF, King AM, et al. A Patient with Alcoholic Ketoacidosis and Profound Lactemia. J Emerg Med 2016;51:447-9. [Crossref] [PubMed]
- Shamoon H, Hendler R, Sherwin RS. Synergistic interactions among antiinsulin hormones in the pathogenesis of stress hyperglycemia in humans. J Clin Endocrinol Metab 1981;52:1235-41. [Crossref] [PubMed]
- Sprague JE, Arbeláez AM. Glucose counterregulatory responses to hypoglycemia. Pediatr Endocrinol Rev 2011;9:463-73; quiz 474-5. [PubMed]
- Rizza RA, Cryer PE, Haymond MW, et al. Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. J Clin Invest 1980;65:682-9. [Crossref] [PubMed]
- Avogaro A, Beltramello P, Gnudi L, et al. Alcohol intake impairs glucose counterregulation during acute insulin-induced hypoglycemia in IDDM patients. Evidence for a critical role of free fatty acids. Diabetes 1993;42:1626-34. [Crossref] [PubMed]
- Rasmussen BM, Orskov L, Schmitz O, et al. Alcohol and glucose counterregulation during acute insulin-induced hypoglycemia in type 2 diabetic subjects. Metabolism 2001;50:451-7. [Crossref] [PubMed]
- Kerr D, Cheyne E, Thomas P, et al. Influence of acute alcohol ingestion on the hormonal responses to modest hypoglycaemia in patients with Type 1 diabetes. Diabet Med 2007;24:312-6. [Crossref] [PubMed]
- Turner BC, Jenkins E, Kerr D, et al. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care 2001;24:1888-93. [Crossref] [PubMed]
- Kolaczynski JW, Ylikahri R, Härkonen M, et al. The acute effect of ethanol on counterregulatory response and recovery from insulin-induced hypoglycemia. J Clin Endocrinol Metab 1988;67:384-8. [Crossref] [PubMed]
- Leppäluoto J, Rapeli M, Varis R, et al. Secretion of anterior pituitary hormones in man: effects of ethyl alcohol. Acta Physiol Scand 1975;95:400-6. [Crossref] [PubMed]
- Ylikahri RH, Huttunen MO, Härkönen M, et al. Acute effects of alcohol on anterior pituitary secretion of the tropic hormones. J Clin Endocrinol Metab 1978;46:715-20. [Crossref] [PubMed]
- Christiansen C, Thomsen C, Rasmussen O, et al. Wine for type 2 diabetic patients? Diabet Med 1993;10:958-61. [Crossref] [PubMed]
- Lao B, Czyzyk A, Szutowski M, et al. Alcohol tolerance in patients with non-insulin-dependent (type 2) diabetes treated with sulphonylurea derivatives. Arzneimittelforschung 1994;44:727-34. [PubMed]
- Czyzyk A, Lao B, Szutowski M, et al. Enhancement of alcohol-induced hypoglycaemia by H2-receptor antagonists. Arzneimittelforschung 1997;47:746-9. [PubMed]
- Jelski W, Orywal K, Szmitkowski M. Effects of H2-blockers on alcohol dehydrogenase (ADH) activity. Pol Merkur Lekarski 2008;25:531-3. [PubMed] doi: 10.21037/jlpm-21-16 Cite this article as: Kalaria T, Ko YL, Issuree KKJ. Literature review: drug and alcohol-induced hypoglycaemia. J Lab Precis Med 2021;6:21.
Cited by
Sorted by citations
Non-Diabetic Hypoglycemia: Evaluation and Management in Adults
Looi, E., & Lawler, H. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134393 · Cited by 10 · see citing works
“These two classes bind to different domains on sulfonylurea receptors expressed on pancreatic β -cells, promoting closure of K ATP channels and subsequent insulin release [18].”
Influential
- Authors
- Kalaria, T., Ko, Y. L., & Issuree, K. K. J.
- Affiliations
- New Cross Hospital (GB)
- The Royal Wolverhampton NHS Trust (GB)
- Corresponding author
- Kalaria, Tejas
- ORCID
- Kalaria, Tejas
- Venue
- Journal of Laboratory and Precision Medicine
- Publisher
- AME Publishing Company
- Published
- 2021-07
- Volume
- 6
- Pages
- 21-21
- ISSN
- 2519-9005 (ISSN-L)
- OpenAlex
- W3178714586
- Cited by
- 17
- References
- 6
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 2
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Journal of Laboratory and Precision Medicine (publishedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Neurological and metabolic disorders
- Keywords
- drug-induced hypoglycaemia, insulin, sulfonylureas, beta-blockers, ACE inhibitors, fibrates, psychotropic drugs, antimalarial drugs, antibiotics, antiarrhythmic drugs, nonsteroidal anti-inflammatory drugs, glucose metabolism, glycogenolysis, gluconeogenesis, counterregulatory hormones, type 1 diabetes, type 2 diabetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review